[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Inenaga C, Morii K, Tamura T, Tanaka R, Takahashi H: Mesenchymal chondrosarcoma of the sellar region. Acta Neurochir (Wien); 2003 Jul;145(7):593-7; discussion 597
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, no such malignant tumour has been described in the sellar region.
  • Upon initial admission, no endocrinological abnormalities were found, and computed tomography and magnetic resonance imaging revealed a mass with calcification in the sella and right cavernous sinus.
  • INTERVENTION: For this malignant tumour, three surgical resections, two sessions of gamma-knife radiosurgery, one session of fractional irradiation, and one cycle of chemotherapy were performed, resulting in only brief arrest of the tumour growth.
  • Pathologically, the tumour consisted of undifferentiated small cells of high cellularity, and islands of hyaline cartilage.
  • CONCLUSION: Although malignant tumours in the sellar region are rare, they should be considered in the differential diagnosis of various sellar tumours typified by non-functioning pituitary adenoma, and mesenchymal chondrosarcoma is one possible candidate.

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12910404.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


2. Yaman E, Benekli M, Coskun U, Sezer K, Ozturk B, Kaya AO, Yildiz R, Uluoglu O, Buyukberber S: Intrasellar plasmacytoma: an unusual presentation of multiple myeloma. Acta Neurochir (Wien); 2008 Sep;150(9):921-4; discussion 924
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Occasionally, they can be misdiagnosed as a nonfunctioning adenoma because of radiological and clinical similarities.
  • Initial diagnosis of a nonfunctioning pituitary adenoma was later overruled by a repeat biopsy, which showed a plasmacytoma.
  • The tumor stained positively for CD138 and kappa light chain.
  • Further studies confirmed the diagnosis of multiple myeloma.
  • The patient was successfully treated with radiotherapy followed by systemic chemotherapy.
  • Because they have different therapeutic implications, extramedullary plasmacytomas involving pituitary gland should be considered in the differential diagnosis of a nonfunctioning pituitary mass.
  • [MeSH-major] Multiple Myeloma / complications. Multiple Myeloma / diagnosis. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / etiology. Plasmacytoma / diagnosis. Plasmacytoma / etiology
  • [MeSH-minor] Adenoma / diagnosis. Aged. Biopsy. Diagnosis, Differential. Female. Humans. Immunoglobulin kappa-Chains / metabolism. Magnetic Resonance Imaging. Sella Turcica. Syndecan-1 / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726062.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains; 0 / Syndecan-1
  • [Number-of-references] 24
  •  go-up   go-down


3. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R: MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary; 2010 Dec;13(4):367-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
  • Recent case reports have documented the efficacy of temozolomide therapy in some aggressive pituitary adenomas and pituitary carcinomas resistant to multimodality therapy.
  • Evidence suggests that low O6-methylguanine-DNA methyltransferase (MGMT) immunoexpression correlates with response to temozolomide chemotherapy.
  • Herein, we aimed to study MGMT immunoexpression in a spectrum of pituitary tumors, indolent, aggressive and malignant.
  • A literature review of the use of temozolomide in pituitary tumors was also performed.
  • Immunohistochemistry for MGMT was performed on 60 pituitary tumors identified in the Mayo Clinic Tissue Registry and the consultation files of one of us (BWS).
  • The group included 30 pituitary carcinomas (15 ACTH, 10 PRL, 1 FSH/LH, 1 TSH, 1 silent subtype 3 and 2 null cell).
  • Tissue from recurrences was available in 17 cases.
  • In addition, 30 functionally different pituitary adenomas were studied, including 15 invasive and 15 non-invasive adenomas.
  • Overall, 32 cases of pituitary tumors (54%) demonstrated low MGMT immunoexpression.
  • This included 17 of 30 (57%) carcinomas, 9 of 15 (60%) invasive adenomas, and 6 of 15 cases (40%) of non-invasive pituitary adenomas.
  • There was no significant change in MGMT immunoexpression between primary and recurrent tumors.
  • Prolactin-producing carcinomas had the highest proportion of tumors (80%) with low expression.
  • A significant proportion of pituitary adenomas and carcinomas demonstrate low MGMT immunoexpression.
  • In an effort to anticipate the likelihood of a temozolomide response, all cases of aggressive pituitary tumors should be assessed for MGMT expression.
  • [MeSH-major] DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Pituitary Neoplasms / immunology. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Humans. Immunohistochemistry. Immunosuppression. Male

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12 ):3851-7 [9850030.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12 ):1470-5 [17442989.001]
  • [Cites] Curr Opin Oncol. 2007 Nov;19(6):606-11 [17906460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Child Neurol. 2008 Dec;23 (12 ):1467-71 [19073854.001]
  • [Cites] Neurosurg Focus. 2004 Apr 15;16(4):E7 [15191336.001]
  • [Cites] J Neurosurg. 2006 Oct;105(4):621-6 [17044568.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Oct;65(4):552-3 [16984254.001]
  • [Cites] World J Surg Oncol. 2007 Aug 04;5:89 [17683572.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Eur J Endocrinol. 2009 Oct;161(4):553-9 [19589911.001]
  • [Cites] DNA Repair (Amst). 2007 Aug 1;6(8):1116-26 [17569599.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] Onkologie. 2007 Jul;30(7):361-6 [17596744.001]
  • [Cites] Lab Invest. 1998 May;78(5):643-4 [9605190.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):59-65 [18091318.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):3089-99 [15741248.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):518-20 [16750503.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Clin Endocrinol (Oxf). 2009 Aug;71(2):226-33 [19067722.001]
  • [Cites] Gut. 2005 Jun;54(6):797-802 [15888787.001]
  • [Cites] Cancer. 2009 Mar 1;115(5):1070-80 [19156926.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2388-99 [11981013.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):354-63 [15915369.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10 (6):1871-4 [15041700.001]
  • [Cites] DNA Repair (Amst). 2007 Aug 1;6(8):1155-60 [17482895.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):401-6 [16421420.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12 (15):4738-46 [16899625.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3431-7 [16849758.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):185-9 [17056093.001]
  • [Cites] Acta Neuropathol. 2008 Feb;115(2):261-2 [17926052.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] Eur J Endocrinol. 2009 Jan;160(1):115-9 [18984772.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1275-80 [16211296.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Neurosurgery. 2009 Apr;64(4):E773-4; discussion E774 [19349807.001]
  • [Cites] Pituitary. 1998 Apr;1(1):69-81 [11081185.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Eur J Endocrinol. 2009 Oct;161(4):631-7 [19654234.001]
  • [Cites] Pituitary. 2007;10 (1):81-6 [17285366.001]
  • [Cites] Ann Neurol. 2006 Dec;60(6):740-3 [17192931.001]
  • [Cites] J Biol Chem. 1994 Jun 24;269(25):17228-37 [8006031.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10 ):2986-91 [17505000.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):818-24 [9062489.001]
  • [Cites] Cancer. 2011 Feb 1;117(3):454-62 [20845485.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):443-8 [16391867.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):1985-90 [17621591.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Dec;83(12 ):4233-8 [9851756.001]
  • (PMID = 20740317.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  •  go-up   go-down


Advertisement
4. Chaidarun SS, Klibanski A: Gonadotropinomas. Semin Reprod Med; 2002 Nov;20(4):339-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advances in immunocytochemistry, electron microscopy, cell culture, and molecular techniques have demonstrated that 80 to 90% of the clinically nonfunctioning pituitary adenomas are gonadotrope-derived and recently recognized as gonadotropinomas, which account for as many as 40 to 50% of all pituitary macroadenomas.
  • Commonly, the tumor is found incidentally.
  • The tumors can be divided into two broad categories: functioning gonadotropinomas with positive immunostaining for follicle-stimulating hormone, leutinizing hormone, and/or their subunits; and nonfunctioning gonadotropinomas or null cell tumors with negative immunostaining for all pituitary hormones but positive nuclear immunostaining for steroid factor-1 or DAX-1 characteristic of gonadotrope differentiation, with evidence of gonadotropin production or gene expression at the mRNA level.
  • Gonadotropinomas are monoclonal in origin but the pathogenesis of these tumors is unknown and factors that stimulate clonal proliferation not yet determined.
  • A new pituitary oncogene, pituitary tumor transforming gene, has recently been found to be overexpressed in about two thirds of these tumors but it is also detected in all other pituitary tumor subtypes.
  • Alterations of tumor hormone receptors and local growth factors may also play a role in the tumor development and/or progression.
  • Transphenoidal surgery remains the principal therapy for the macroadenomas.
  • Radiosurgery using gamma knife, the linear accelerator, or proton beam therapy showed promising results, especially for controlling the residual or recurrent tumors.
  • Medical therapy with somatostatin analogs, dopamine agonists, and gonadotropin-releasing hormone agonists and antagonists are rarely effective in reducing tumor size.
  • Experimental therapy with intraoperative local chemotherapy or potential gene therapy requires further investigation.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / etiology. Gonadotropins, Pituitary / metabolism. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12536357.001).
  • [ISSN] 1526-8004
  • [Journal-full-title] Seminars in reproductive medicine
  • [ISO-abbreviation] Semin. Reprod. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadotropins, Pituitary
  • [Number-of-references] 88
  •  go-up   go-down


5. Zhang W, Murao K, Imachi H, Iwama H, Chen K, Fei Z, Zhang X, Ishida T, Tamiya T: Suppression of prolactin expression by cabergoline requires prolactin regulatory element-binding protein (PREB) in GH3 cells. Horm Metab Res; 2010 Jul;42(8):557-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prolactin regulatory element-binding protein (PREB) is a transcriptional factor that regulates prolactin (PRL) promoter activity in the anterior pituitary.
  • Prolactinomas are the most common pituitary tumors.
  • Administration of cabergoline, a selective dopamine D2-receptor agonist, has become the initial therapy of choice for most patients with prolactinomas.
  • Samples of ten prolactinomas and ten nonfunctioning pituitary adenomas were analyzed by immunohistochemistry to detect the expression of PREB.
  • The effect of cabergoline on PREB expression was assessed by western blotting and real-time polymerase chain reaction (PCR) analysis.
  • Immunohistochemical analysis revealed strong positive PREB expression in the prolactinoma tissue, but extremely weak or undetected expression in the nonfunctioning pituitary tumor tissue.
  • Western blots probed with a PREB-specific antiserum revealed that the relative abundance of the PREB protein in the GH3 cells decreased in a dose-dependent manner in response to cabergoline treatment, as did the relative abundance of PREB mRNA.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Down-Regulation / drug effects. Ergolines / pharmacology. Guanine Nucleotide Exchange Factors / metabolism. Prolactin / genetics. Transcription Factors / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Prolactinoma / metabolism. Prolactinoma / pathology. Promoter Regions, Genetic / genetics. Transcription, Genetic / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20411477.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Ergolines; 0 / Guanine Nucleotide Exchange Factors; 0 / PREB protein, human; 0 / Transcription Factors; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  •  go-up   go-down


6. Svensson J, Finer N, Bouloux P, Bevan J, Jonsson B, Mattsson AF, Lundberg M, Harris PE, Koltowska-Häggström M, Monson JP, KIMS International Board: Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Horm IGF Res; 2007 Feb;17(1):67-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response.
  • OBJECTIVE: This study investigated whether baseline status could predict the responsiveness to one-year growth hormone (GH) replacement therapy in adult GH deficient (GHD) patients.
  • DESIGN: A total of 380 European patients with adult onset GHD due to non-functioning pituitary adenoma that had been enrolled in Pfizer International Metabolic Database (KIMS), and that had completed one year of GH replacement therapy within KIMS, were studied.
  • Quality of life (QoL)-Assessment of GHD in Adults (QoL-AGHDA), waist circumference, waist:hip ratio, and serum lipid pattern improved.
  • Women received a higher dose of GH than men after one year, and demonstrated similar treatment response.
  • In multiple stepwise forward regression analyses, the one-year changes in QoL-AGHDA score, waist:hip ratio, and serum low density lipoprotein-cholesterol (LDL-C) level correlated inversely with the baseline values of the same variable.
  • In addition, the change after one year in QoL-AGHDA score correlated inversely with duration of hypopituitarism and baseline serum high density lipoprotein-cholesterol (HDL-C) level, and the change in waist:hip ratio correlated inversely, although more weakly, with baseline serum HDL-C level and UK citizenship and positively with baseline waist circumference and the initial GH dose.
  • Therefore, when the decision to start GH replacement is undertaken, as many outcome variables as possible should be evaluated in order to adequately evaluate the likelihood of clinical benefit.
  • Finally, women have a similar response to GH replacement as men when individualised GH dosing schedules are employed and should therefore be selected for GH therapy to a similar extent.
  • [MeSH-major] Dwarfism, Pituitary / diagnosis. Dwarfism, Pituitary / drug therapy. Growth Hormone / therapeutic use. Hormone Replacement Therapy
  • [MeSH-minor] Cohort Studies. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Models, Statistical. Prognosis. Quality of Life. Sex Characteristics. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223598.001).
  • [ISSN] 1096-6374
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


7. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M: The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res; 2010 Jan 15;70(2):666-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells.
  • Rapamycin and its analogues have significant antiproliferative action against a variety of tumors.
  • Here, we investigated this model using the somatostatin analogue octreotide as a tool to decrease levels of activated Ser(473)-phosphorylated Akt (pAkt-Ser(473)) in pituitary tumor cells that express somatostatin receptors.
  • Octreotide potentiated the antiproliferative effects of rapamycin in immortalized pituitary tumor cells or human nonfunctioning pituitary adenoma cells in primary cell culture, sensitizing tumor cells even to low rapamycin concentrations.
  • Combined treatment of octreotide and rapamycin triggered G(1) cell cycle arrest, decreasing E2F transcriptional activity and cyclin E levels by increasing levels of p27/Kip1.
  • These findings show that adjuvant treatment with a somatostatin analogue can sensitize pituitary tumor cells to the antiproliferative effects of rapamycin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Octreotide / pharmacology. Pituitary Neoplasms / drug therapy. Sirolimus / pharmacology
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / metabolism. Adenoma / pathology. Cell Cycle / drug effects. Cell Growth Processes / drug effects. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis. Drug Synergism. Humans. Insulin Receptor Substrate Proteins / metabolism. Oncogene Protein v-akt / metabolism. Phosphorylation / drug effects. Up-Regulation


8. Saeger W: [Pituitary gland tumors]. Pathologe; 2003 Jul;24(4):255-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pituitary gland tumors].
  • Pituitary adenomas must be clearly differentiated from other tumors of the sellar region (especially meningiomas, granular cell tumors, chordomas and germinomas), which may look very similar.
  • The sub-classification of adenomas depends on the methods used, in particular the immunostaining for pituitary hormones.
  • This sub-classification is not necessary in every case, but must be performed if unusual findings are observed during surgery or if surgery is unsuccessful and radiation or drug-therapy is planned.
  • Special structures and non-immunohistochemical stainings are very helpful for typing adenomas.
  • We differentiated monohormonal densely or sparsely granulated GH-cell adenomas, monohormonal sparsely or very rarely densely granulated prolactin cell adenomas, monohormonal densely or sparsely ACTH-cell adenomas, monohormonal TSH-cell adenomas and FSH/LH cell adenomas from bihormonal adenomas of mammosomatotroph or GH/prolactin cell type or of the acidophil stem cell adenoma type.
  • The number of plurihormonal adenomas decreased with the use of improved monoclonal antibodies.
  • Clinically inactive adenomas are classified as null cell adenomas, oncocytic adenomas or FSH/LH-cell adenomas.
  • These appear as subtypes of one entity deriving from the gonadotroph cell type.
  • Craniopharyngiomas are classified into adamantinous and papillary types, which are not only structurally but also clinically different.
  • [MeSH-major] Pituitary Neoplasms / pathology
  • [MeSH-minor] Adenoma / pathology. Adenoma / secretion. Diagnosis, Differential. Humans. Pituitary Hormones / secretion. Sella Turcica / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1981;54(3):257-60 [6167138.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1313-8; discussion 1318-9 [11126902.001]
  • [Cites] Pathol Res Pract. 1991 Jun;187(5):632-6 [1923959.001]
  • [Cites] Endocr Pathol. 1996 Spring;7(1):21-35 [12114677.001]
  • [Cites] Pathol Res Pract. 1988 Sep;183(5):592-5 [3237549.001]
  • [Cites] Pathologe. 1997 Nov;18(6):419-24 [9451729.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):135-143 [12114649.001]
  • [Cites] Exp Clin Endocrinol. 1988 Aug;91(3):341-9 [3251773.001]
  • [Cites] Endocr Pathol. 2000 Autumn;11(3):215-227 [12114694.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 May;128(5):411-7 [8317187.001]
  • [Cites] Gen Diagn Pathol. 1995 Oct;141(2):81-92 [8548598.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(2):147-51 [11459086.001]
  • [Cites] Pituitary. 1999 May;1(3-4):213-20 [11081200.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jan;110(1):72-5 [3510059.001]
  • [Cites] Pathol Res Pract. 1993 Nov;189(9):1044-51 [8302723.001]
  • [Cites] Pathologe. 2001 Sep;22(5):296-309 [11572110.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(4):417-31 [2426859.001]
  • [Cites] Neurosurgery. 1993 Nov;33(5):920-4; discussion 924-5 [8264895.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Apr;54(4):479-84 [11318783.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):677-83; discussion 683-4 [7596496.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;394(3):255-67 [6280372.001]
  • (PMID = 14513271.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Pituitary Hormones
  • [Number-of-references] 27
  •  go-up   go-down


9. Lin SH, Hung YH, Lin YF: Severe hyponatremia as the presenting feature of clinically non-functional pituitary adenoma with hypopituitarism. Clin Nephrol; 2002 Jan;57(1):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hyponatremia as the presenting feature of clinically non-functional pituitary adenoma with hypopituitarism.
  • We present two cases in which severe hyponatremia developed with weakness, light-headedness and seizure.
  • Computerized tomography of the brain revealed an adenoma of the pituitary gland.
  • These two cases illustrate that severe hyponatremia may be the presenting feature of clinically non-functional pituitary adenoma with hypopituitarism, which should be kept in mind in the differential diagnosis of hyponatremia mimicking SIADH.
  • [MeSH-major] Adenoma / complications. Hyponatremia / etiology. Pituitary Neoplasms / complications
  • [MeSH-minor] Aged. Anti-Inflammatory Agents / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Thyroid Hormones / therapeutic use. Thyroxine / administration & dosage. Vasopressins / blood. Vasopressins / deficiency

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11837807.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Thyroid Hormones; 11000-17-2 / Vasopressins; 9PHQ9Y1OLM / Prednisolone; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


10. Gur C, Lalazar G, Salmon A, Dubiner V, Gross DJ: Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report. Pituitary; 2008;11(3):293-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report.
  • Neuroendocrine tumor metastases to the pituitary gland are very rare.
  • There are few case reports of carcinoid tumor metastases to the pituitary, but no cases of pancreatic neuroendocrine pituitary metastases have been reported.
  • In this report we present a 55-year-old female with a sellar mass, ophthalmoplegia and headaches initially thought to represent an invasive null cell pituitary adenoma.
  • However a histological (trans-sphenoidal and liver biopsies) and systemic investigation proved it to be a metastasis of an undiagnosed pancreatic neuroendocrine tumor.
  • Our patient was unique in respect to the location of the metastasis and the uncharacteristically high proliferative index of her tumor.
  • She received conventional therapy consisting of Sandostatin, chemotherapy and radiotherapy as well as labeled somatostatin following an avid uptake on octreotide scanning.
  • [MeSH-major] Neuroendocrine Tumors / secondary. Pancreatic Neoplasms / pathology. Pituitary Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Middle Aged. Radiotherapy, Adjuvant. Tomography, Emission-Computed, Single-Photon


11. Deniz K, Tanriverdi F, Selçuklu A, Kontaş O, Keleştimur F: Signet ring-like cells in pituitary adenoma. Pathol Res Pract; 2008;204(3):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet ring-like cells in pituitary adenoma.
  • We describe a case of non-functioning pituitary adenoma in a 35-year-old woman with a prior history of fertility problems.
  • Histological examination of the tumor revealed signet ring-like cell areas admixed with minor conventional round-polygonal neoplastic cells.
  • The two populations of tumor cells showed strong immunoreactivity for chromogranin and synaptophysin.
  • [MeSH-major] Adenoma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adult. Chorionic Gonadotropin / therapeutic use. Chromogranins / metabolism. Clomiphene / therapeutic use. Female. Fertility Agents, Female / therapeutic use. Headache / etiology. Humans. Immunohistochemistry. Infertility, Female / drug therapy. Magnetic Resonance Imaging. Synaptophysin / metabolism. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. CLOMIPHENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207654.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chromogranins; 0 / Fertility Agents, Female; 0 / Synaptophysin; 1HRS458QU2 / Clomiphene
  •  go-up   go-down


12. Trimarchi CP, Russo P: Cyclic estrogen-progestin hormone therapy as a new therapeutic approach in the treatment of functional alterations of the hypothalamus-pituitary-ovary axis: case reports. Endocr Res; 2002 Aug;28(3):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclic estrogen-progestin hormone therapy as a new therapeutic approach in the treatment of functional alterations of the hypothalamus-pituitary-ovary axis: case reports.
  • We report a first case of a 30 year-old woman affected by polycystic ovarian disease (PCOD) whose amenorrhea ceased after a 6-month combination treatment with cyclic estradiol-norethisterone acetate.
  • After the withdrawal of the hormone therapy, a stable recovery of periodic menses was observed.
  • We describe a second case of a 23 year-old woman whose amenorrhea was caused by a hypogonadotropic hypogonadism due to a non-functioning pituitary adenoma.
  • After the administration of the previously described therapy both a disappearance of the adenoma and a recover of periodic menses were observed.
  • The exogenous hormones may have reset the feedback between the hypothalamus and pituitary gland through mimicking the physiological hormones pattern of the 28-day cycle.
  • [MeSH-major] Adenoma / complications. Amenorrhea / drug therapy. Estradiol / administration & dosage. Norethindrone / administration & dosage. Norethindrone / analogs & derivatives. Pituitary Neoplasms / complications. Polycystic Ovary Syndrome / complications
  • [MeSH-minor] Adult. Drug Administration Schedule. Drug Therapy, Combination. Feedback. Female. Humans. Hypogonadism / complications. Hypothalamus / drug effects. Hypothalamus / physiopathology. Ovary / physiopathology. Pituitary Gland / drug effects. Pituitary Gland / physiopathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. NORETHINDRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12489565.001).
  • [ISSN] 0743-5800
  • [Journal-full-title] Endocrine research
  • [ISO-abbreviation] Endocr. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9S44LIC7OJ / norethindrone acetate; T18F433X4S / Norethindrone
  •  go-up   go-down


13. Guerra Y, Lacuesta E, Marquez F, Raksin PB, Utset M, Fogelfeld L: Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary; 2010;13(1):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
  • We report the case of a 60 year old male who complained of headache and blurry vision--that progressed to left ophthalmoplegia and ptosis--after receiving a dose of leuprolide for Prostate cancer therapy.
  • The patient underwent transsphenoidal debulking, and the tissue obtained demonstrated immunohistochemical staining for LH.
  • A literature review revealed nine previously reported cases of pituitary apoplexy after GnRH agonist therapy for prostate cancer.
  • In most cases, the sellar tissues stained for LH, consistent with a gonadotropinoma.
  • Particular attention to clinical findings suggestive of a non functioning pituitary tumor in patients receiving GnRH agonist therapy is critical as routine screening with MRI is not practical.
  • [MeSH-major] Adenoma / complications. Leuprolide / adverse effects. Pituitary Neoplasms / complications. Stroke / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Humans. Male. Middle Aged. Prostatic Neoplasms / complications. Prostatic Neoplasms / drug therapy. Sella Turcica


14. Colao A, Dorato M, Pulcrano M, Rossi FW, Auriemma RS, Lombardi G, Lastoria S: [Somatostatin analogs in the clinical management of pituitary neoplasms]. Minerva Endocrinol; 2001 Sep;26(3):181-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Somatostatin analogs in the clinical management of pituitary neoplasms].
  • The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs.
  • Good results were obtained using slow-release analog treatment also in TSH-secreting adenomas, whereas the therapeutic efficacy of these peptides in clinically non-functioning adenomas is still controversial.
  • Treatment with somatostatin analogs improves symptoms, normalises hormone secretion and in some cases may induce a reduction in the volume of pituitary adenomas.
  • Scintigraphy with octreotide may help to select patients who respond to this form of treatment.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / analogs & derivatives. Octreotide / therapeutic use. Pentetic Acid / analogs & derivatives. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Acromegaly / drug therapy. Adolescent. Adrenal Gland Neoplasms / radionuclide imaging. Adult. Aged. Carcinoma / radionuclide imaging. Humans. Indium Radioisotopes / therapeutic use. Insulin-Like Growth Factor I / secretion. Kidney Neoplasms / radionuclide imaging. Melanoma / radionuclide imaging. Middle Aged. Pheochromocytoma / radionuclide imaging. Predictive Value of Tests. Prolactinoma / drug therapy. Radiopharmaceuticals / therapeutic use. Sensitivity and Specificity. Thymoma / radionuclide imaging. Thymus Neoplasms / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Thyrotropin / secretion. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11753242.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Indium Radioisotopes; 0 / Peptides, Cyclic; 0 / Radiopharmaceuticals; 118992-92-0 / lanreotide; 142694-57-3 / SDZ 215-811; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 7A314HQM0I / Pentetic Acid; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 95
  •  go-up   go-down


15. Kreitschmann-Andermahr I, Poll EM, Reineke A, Gilsbach JM, Brabant G, Buchfelder M, Fassbender W, Faust M, Kann PH, Wallaschofski H: Growth hormone deficient patients after traumatic brain injury--baseline characteristics and benefits after growth hormone replacement--an analysis of the German KIMS database. Growth Horm IGF Res; 2008 Dec;18(6):472-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All 84 TBI patients were matched with 84 patients with GHD due to non-functioning pituitary adenoma (NFPA) also included in this database.
  • Analysis of clinical and outcome variables was performed, with comparisons of childhood vs. adult TBI, and TBI vs. NFPA patients, at baseline and one-year follow-up.
  • RESULTS: TBI patients with GHD were significantly younger at the onset of pituitary disease and exhibited a significantly longer time span between GHD diagnosis and KIMS entry than NFPA patients.
  • At 1-year follow-up, insulin-like growth factor I (IGF-I) standard deviation score levels had returned to the normal range and quality of life (QoL), as measured by QoL- Assessment of Growth Hormone Deficiency in Adults (AGHDA) questionnaire, improved significantly in TBI as in NFPA patients.
  • CONCLUSION: This analysis provides preliminary data that TBI patients with GHD benefit from hGH replacement in terms of improved QoL in a similar fashion as do NFPA patients.
  • Moreover, it suggests that belated diagnosis and treatment in childhood-onset GHD due to TBI might be related to a shorter final height in these children.
  • [MeSH-major] Brain Injuries / physiopathology. Databases, Factual. Human Growth Hormone / therapeutic use
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Germany. Hormone Replacement Therapy. Humans. Hypopituitarism / complications. Hypopituitarism / drug therapy. Hypopituitarism / physiopathology. Male. Middle Aged. Pituitary Neoplasms / complications. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829359.001).
  • [ISSN] 1532-2238
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down






Advertisement